

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC and AMNEAL  
PHARMACEUTICALS OF NEW YORK, LLC,  
Petitioners,

v.

ALMIRALL, LLC  
Patent Owner

---

Case IPR2019-00207  
U.S. Pat. No. 9,517,219

---

**PETITIONERS' EXHIBIT LIST**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

<i>Amneal Exhibit #</i>	<i>Description</i>
<b>1001</b>	U.S. Patent No. 9,517,219
<b>1002</b>	Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
<b>1003</b>	<i>Curriculum Vitae</i> for Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
<b>1004</b>	International Patent Application Publication No. WO 2009/061298 (“Garrett”)
<b>1005</b>	International Application Publication No. WO 2010/072958 (“Nadau-Fourcade”)
<b>1006</b>	Certification for Translation of WO 2010/072958
<b>1007</b>	U.S. Patent Publication No. 2006/0204526 (“Lathrop”)
<b>1008</b>	U.S. Patent Publication No. 2010/0029781 (“Morris”)
<b>1009</b>	Osborne, D.W., “Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products,” <i>J. Cosmetic Derm.</i> 10:324-329 (2011) (“Osborne I”)
<b>1010</b>	<i>Physician’s Desk Reference</i> , 65 <sup>th</sup> ed., pp. 599-602 (2011) (ACZONE Gel 5% Label)
<b>1011</b>	U.S. Patent No. 7,820,186 (“Orsoni”)
<b>1012</b>	Epiduo Product Label, approved December 8, 2008 (“Epiduo Label”)
<b>1013</b>	U.S. Patent Publication No. 2007/0190019 (“Guo”)
<b>1014</b>	Rowe, R.C. et al. (Eds.), <i>Handbook of Pharmaceutical Excipients</i> , 6th Ed., Pharmaceutical Press: London, UK (2009)
<b>1015</b>	Bonacucina, G., <i>et al.</i> , “Characterization and Stability of Emulsion Gels Based on Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer,” <i>AAPS PharmaSciTech</i> 10:368-375 (2009) (“Bonacucina”)
<b>1016</b>	U.S. Patent No. 5,863,560 (“Osborne II”)
<b>1017</b>	File History of U.S. Patent No. 9,517,219
<b>1018</b>	Declaration of Elaine S. Gilmore, M.D., Ph.D.

<i>Amneal Exhibit #</i>	<i>Description</i>
<b>1019</b>	<i>Curriculum Vitae</i> for Elaine S. Gilmore, M.D., Ph.D.
<b>1020</b>	Affidavit of Christopher Butler
<b>1021</b>	<i>Intentionally left blank</i>
<b>1022</b>	Wozel, D., "Innovative Use of Dapsone" <i>Dermatol. Clin.</i> 28: 599–610 (2010) ("Wozel")
<b>1023</b>	Thiboutot, D., <i>et al.</i> , "Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris" <i>Clin. Pharmacokinet.</i> 46: 697-712 (2007) ("Thiboutot")
<b>1024</b>	Nguyen, R. and Su, J., "Treatment of Acne Vulgaris" <i>Pediatrics and Child Health</i> 21: 119-125 (2010) ("Nguyen")
<b>1025</b>	Williams, H., <i>et al.</i> , "Acne vulgaris" <i>Lancet</i> 379: 361–72 (2012) ("Williams")
<b>1026</b>	Sepineo™ P 600 Brochure
<b>1027</b>	Barclay, L., "Use of Topical Corticosteroids for Dermatologic Conditions Reviewed" <i>Medscape</i> - Jan 21, 2009, accessed from <a href="https://www.medscape.com/viewarticle/587159_print">https://www.medscape.com/viewarticle/587159_print</a> ("Barclay")
<b>1028</b>	Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins: Baltimore, MD (2005) ("Remington")
<b>1029</b>	Kim, J-Y., <i>et al.</i> , "Rheological properties and microstructures of Carbopol gel network system," <i>Colloid. Polym. Sci.</i> 281:614–623(2003) ("Kim")
<b>1030</b>	<i>Intentionally left blank</i>
<b>1031</b>	Spain's Almirall bets on dermatology with \$650 million U.S. deal, Retrieved from <a href="https://www.reuters.com/article/us-allergan-m-a-almirall/spains-almirall-bets-on-dermatology-with-650-million-us-deal-idUSKBN1KO10N">https://www.reuters.com/article/us-allergan-m-a-almirall/spains-almirall-bets-on-dermatology-with-650-million-us-deal-idUSKBN1KO10N</a> , last accessed October 26, 2018
<b>1032</b>	Piskin, S. <i>et al.</i> "A review of the use of adapalene for the treatment of acne vulgaris," <i>Therapeutics and Clinical Risk Management</i> 3(4): 621–624 (2007) ("Piskin")
<b>1033</b>	<i>Intentionally left blank</i>

<i>Amneal Exhibit #</i>	<i>Description</i>
<b>1034</b>	Andersson, D., "Evonik-Degussa expands its cooperation with Alsiano," <i>Pharma &amp; Healthcare News</i> : 1-10 (2007)
<b>1035</b>	Poster Abstracts for the Journal of the American Academy of Dermatology 2017 Annual Meeting
<b>1036</b>	Email dated October 8, 2019 from Liz Hagan to Tyler Liu, Dennies Varughese, Adam LaRock and James Trainor regarding conference call
<b>1037</b>	Email dated October 8, 2019 from Tyler Liu to <a href="mailto:trials@uspto.gov">trials@uspto.gov</a> requesting authorization to file a motion for additional discovery
<b>1038</b>	<i>Almirall, LLC v. Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals, Inc.</i> , Case 1:17-cv-00663 [Proposed] Joint Pretrial Order, Document 142, February 5, 2019
<b>1039</b>	Deposition Transcript for Leon H. Kircik, M.D., Case IPR2019-00207 (October 4, 2019)
<b>1040</b>	Deposition Transcript for David W. Osborne, Ph.D., Case IPR2019-00207 (October 18, 2019)
<b>1041<sup>1</sup></b>	Allergan Announces Agreement to Acquire Aczone® Gel 5%, Retrieved from <a href="https://www.businesswire.com/news/home/20080609005407/en/Allergan-Announces-Agreement-Acquire-Aczone-Gel-5">https://www.businesswire.com/news/home/20080609005407/en/Allergan-Announces-Agreement-Acquire-Aczone-Gel-5</a> , last accessed on October 7, 2019
<b>1042</b>	U.S. Patent No. 7,326,408
<b>1043</b>	Second Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
<b>1044</b>	Second Declaration of Elaine S. Gilmore, M.D., Ph.D.

---

<sup>1</sup> Exhibits 1041 and 1042 were served on counsel for Almirall on October 18, 2019.

<i>Amneal Exhibit #</i>	<i>Description</i>
<b>1045</b>	Inactive Ingredient Search for Approved Drug Products: Frequently Asked Questions, Retrieved from <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-search-approved-drug-products-frequently-asked-questions#inactive%20as%20active?">https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-search-approved-drug-products-frequently-asked-questions#inactive%20as%20active?</a> , last accessed on October 25, 2019
<b>1046</b>	Lubrizol Technical Data Sheet, Dispersion Techniques for Carbopol® Polymers
<b>1047</b>	Kircik, L.H., “Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment,” <i>Journal of Drugs in Dermatology</i> 15(2):191-195 (2016)
<b>1048</b>	Tanghetti, E., <i>et al.</i> , “The Efficacy and Tolerability of Dapsone 5% Gel in Female vs. Male Patients With Facial Acne Vulgaris: Gender as a Clinically Relevant Outcome Variable,” <i>Journal of Drugs in Dermatology</i> 11:1417-1421 (2012)
<b>1049</b>	<i>Intentionally left blank</i>
<b>1050</b>	Neutralizing Carbopol® and Pemulen® Polymers in Aqueous and Hydroalcoholic Systems, published January 2002 (“Noveon Technical Data Sheet”)
<b>1051</b>	2010 Inactive Ingredient Database, available at: <a href="http://wayback.archive-it.org/7993/20170112022245/http://www.fda.gov/Drugs/InformationOnDrugs/ucml13978.htm">http://wayback.archive-it.org/7993/20170112022245/http://www.fda.gov/Drugs/InformationOnDrugs/ucml13978.htm</a> .
<b>1052</b>	FDA Drug Master File Database, available at: <a href="https://www.fda.gov/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/default.htm">https://www.fda.gov/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/default.htm</a> .
<b>1053</b>	Sullivan, D., <i>et al.</i> , “A review of the nonclinical safety of Transcutol®, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient,” <i>Food and Chemical Toxicology</i> 72: 4-50 (2014)
<b>1054</b>	FDA Inactive Ingredient Database Field Descriptions
<b>1055</b>	Andersson, D., “Evonik-Degussa expands its cooperation with Alsiano,” <i>Pharma &amp; Healthcare News</i> 7:1-10 (2007)
<b>1056</b>	File History of U.S. Patent No. 9,161,926
<b>1057</b>	Deposition Transcript for Julie C. Harper, M.D., Case IPR2018-00608 (March 11, 2019)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.